Canaccord lowered the firm’s price target on Aurora Cannabis (ACB) to C$9 from C$10 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACB:
- Aurora Cannabis: Divestiture-Driven Margin Uplift and Improved Growth Outlook Support Buy Rating
- Aurora Cannabis Earnings Call Highlights Medical-First Pivot
- Aurora Cannabis Sets Up US$100 Million ATM Equity Program With TD Securities
- Aurora Cannabis Launches US$100 Million At-the-Market Equity Program to Fund Growth
- Aurora Cannabis Q3 Results Highlight Record Medical Revenue and Strategic Refocus on Core Markets